Literature DB >> 3315189

Abnormal insulin-receptor down regulation and dissociation of down regulation from insulin biological action in cultured human tumor cells.

K G Mountjoy1, G J Finlay, I M Holdaway.   

Abstract

The sensitivity of insulin receptors to down regulation by insulin has been measured in cultured human tumor cells (breast tumor cell lines MCF-7, T-47D, and colon tumor cell line HCT-8). Insulin receptors on breast tumor cells were resistant to down regulation (15-17% maximum loss of insulin binding after 4 h exposure to 170 nM insulin). HCT-8 cells were sensitive to down regulation after 4 h exposure to 3.8 nM insulin, but the extent of down regulation then lessened at higher concentrations of insulin. This paradoxical behavior was associated with increasing affinity of insulin receptors for insulin following exposure to hormone. Insulin-stimulated [3H]leucine incorporation into protein was measured in parallel with studies of receptor regulation to assess the effect of preexposure of cells to insulin on cell metabolism. Maximum down regulation of receptors in all three types of tumor cell by prior exposure to insulin did not significantly alter the responsiveness of any of the cell lines to insulin. Thus insulin receptor down regulation is abnormal in these tumor lines compared with reported studies in normal cells, and this may contribute a metabolic advantage to these malignant cells over normal tissues.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A.

Authors:  Alaide Morcavallo; Marco Genua; Angela Palummo; Emilia Kletvikova; Jiri Jiracek; Andrzej M Brzozowski; Renato V Iozzo; Antonino Belfiore; Andrea Morrione
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

2.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

4.  Growth stimulation of primary rat hepatocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  D Wölfle; E Becker; C Schmutte
Journal:  Cell Biol Toxicol       Date:  1993 Jan-Mar       Impact factor: 6.691

5.  Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study.

Authors:  Rachel Dankner; Michael H Shanik; Lital Keinan-Boker; Cindy Cohen; Angela Chetrit
Journal:  Diabetes Care       Date:  2012-05-22       Impact factor: 19.112

6.  Insulin-tumour interrelationship in EL4 lymphoma or thymoma-bearing mice. I. Alloxan-diabetic or non-diabetic mice.

Authors:  D Yam; A Zilberstein; A Fink; I Nir
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

Review 7.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

8.  MiR-221 Expression Level Correlates with Insulin-Induced Doxorubicin Resistance in MCF-7 Breast Cancer Cells.

Authors:  Parisa Kheradmand; Sadeq Vallian Boroojeni; Saeed Esmaeili-Mahani
Journal:  Cell J       Date:  2021-07-17       Impact factor: 2.479

9.  Insulin-tumour interrelationships in thymoma bearing mice. Effects of dietary glucose and fructose.

Authors:  D Yam; A Fink; I Nir; P Budowski
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

10.  Insulin-like growth factor I activates the invasion suppressor function of E-cadherin in MCF-7 human mammary carcinoma cells in vitro.

Authors:  M E Bracke; B M Vyncke; E A Bruyneel; S J Vermeulen; G K De Bruyne; N A Van Larebeke; K Vleminckx; F M Van Roy; M M Mareel
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.